Echo Therapeutics Inc  

(Public, NASDAQ:ECTE)   Watch this stock  
Find more results for Alan Goldberg
-0.06 (-3.49%)
Oct 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.66 - 1.75
52 week 0.50 - 3.00
Open 1.74
Vol / Avg. 0.00/18,671.00
Mkt cap 19.14M
P/E     -
Div/yield     -
EPS -2.39
Shares 11.13M
Beta 1.24
Inst. own 16%
Sep 10, 2015
Echo Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Aug 14, 2015
Q2 2015 Echo Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -26103.72%
Operating margin - -21493.25%
EBITD margin - -20808.10%
Return on average assets -673.96% -83.86%
Return on average equity -1942.84% -106.24%
Employees 18 -
CDP Score - -


99 Wood Ave S Ste 302
ISELIN, NJ 08830-2715
United States - Map
+1-732-5490919 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Echo Therapeutics, Inc. (Echo) is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market and the diabetes outpatient market. The Company offers continuous glucose monitoring, drug delivery and specialty pharmaceutical products. The Company's lead product is a non-invasive (needle-free), wireless, continuous glucose monitoring system designed to provide real-time glucose data. The Company's skin preparation device also has application in the transdermal drug delivery market. The Company's transdermal drug reformulation platform, AzoneTS, is a penetration enhancer at low concentration levels. The Company's drug candidate, Durhalieve is an AzoneTS formulation of triamcinolone acetonide, a medium potency corticosteroid for treatment of corticosteroid-responsive dermatoses.

Officers and directors

Scott W. Hollander President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Alan W. Schoenbart CPA Chief Financial Officer, Secretary
Age: 56
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Shepard M. Goldberg Independent Director
Age: 60
Bio & Compensation  - Reuters